NASDAQ:ACER - Acer Therapeutics Stock Price, Forecast & News

Acer Therapeutics trades on the NASDAQ under the ticker symbol "ACER."

Acer Therapeutics Inc (NASDAQ:ACER) released its earnings results on Wednesday, November, 13th. The biopharmaceutical company reported ($0.52) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.57) by $0.05. View Acer Therapeutics' Earnings History.

Acer Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Acer Therapeutics.

5 brokerages have issued twelve-month price targets for Acer Therapeutics' shares. Their forecasts range from $9.00 to $48.00. On average, they expect Acer Therapeutics' share price to reach $26.75 in the next year. This suggests a possible upside of 532.4% from the stock's current price. View Analyst Price Targets for Acer Therapeutics.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acer Therapeutics in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Acer Therapeutics.

Media headlines about ACER stock have trended very negative this week, InfoTrie Sentiment reports. The research group identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Acer Therapeutics earned a coverage optimism score of -3.7 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 2.0 out of 10, meaning that recent press coverage is very unlikely to have an effect on the company's share price in the next few days. View News Stories for Acer Therapeutics.

Acer Therapeutics saw a decrease in short interest in December. As of December 31st, there was short interest totalling 442,900 shares, a decrease of 8.8% from the December 15th total of 485,900 shares. Based on an average daily volume of 49,800 shares, the short-interest ratio is presently 8.9 days. Currently, 9.1% of the shares of the stock are sold short. View Acer Therapeutics' Current Options Chain.

Some companies that are related to Acer Therapeutics include Harrow Health (HROW), Arcturus Therapeutics (ARCT), Monopar Therapeutics (MNPR), Ovid Therapeutics (OVID), ContraFect (CFRX), Akorn (AKRX), Corvus Pharmaceuticals (CRVS), TAIWAN LIPOSOME/S (TLC), Strongbridge Biopharma (SBBP), Mustang Bio (MBIO), Aldeyra Therapeutics (ALDX), Adamas Pharmaceuticals (ADMS), PhaseBio Pharmaceuticals (PHAS), NuCana (NCNA) and Galectin Therapeutics (GALT).

Based on aggregate information from My MarketBeat watchlists, some companies that other Acer Therapeutics investors own include Sarepta Therapeutics (SRPT), Synergy Pharmaceuticals (SGYP), NovaBay Pharmaceuticals (NBY), Actinium Pharmaceuticals (ATNM), Novavax (NVAX), Arena Pharmaceuticals (ARNA), Madrigal Pharmaceuticals (MDGL), NVIDIA (NVDA), Advanced Micro Devices (AMD) and Amarin (AMRN).

Shares of ACER can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ACER stock can currently be purchased for approximately $4.23.

Acer Therapeutics has a market capitalization of $42.72 million. The biopharmaceutical company earns $-21,280,000.00 in net income (profit) each year or ($2.49) on an earnings per share basis. Acer Therapeutics employs 23 workers across the globe.View Additional Information About Acer Therapeutics.

The official website for Acer Therapeutics is http://www.acertx.com/.

Acer Therapeutics' mailing address is 300 WASHINGTON STREET SUITE 351, NEWTON MA, 02458. The biopharmaceutical company can be reached via phone at 844-902-6100 or via email at [email protected]